311 reports of this reaction
2.1% of all GLECAPREVIR AND PIBRENTASVIR reports
#6 most reported adverse reaction
RASH is the #6 most commonly reported adverse reaction for GLECAPREVIR AND PIBRENTASVIR, manufactured by AbbVie Inc.. There are 311 FDA adverse event reports linking GLECAPREVIR AND PIBRENTASVIR to RASH. This represents approximately 2.1% of all 15,159 adverse event reports for this drug.
Patients taking GLECAPREVIR AND PIBRENTASVIR who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH is a less commonly reported adverse event for GLECAPREVIR AND PIBRENTASVIR, but still significant enough to appear in the safety profile.
In addition to rash, the following adverse reactions have been reported for GLECAPREVIR AND PIBRENTASVIR:
The following drugs have also been linked to rash in FDA adverse event reports:
RASH has been reported as an adverse event in 311 FDA reports for GLECAPREVIR AND PIBRENTASVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH accounts for approximately 2.1% of all adverse event reports for GLECAPREVIR AND PIBRENTASVIR, making it a notable side effect.
If you experience rash while taking GLECAPREVIR AND PIBRENTASVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.